This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hennessy, B. T. Articles by Hortobagyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Hennessy, B. T. Articles by Hortobagyi, G. N.

Squamous Cell Carcinoma of the Breast

From the Departments of Breast Medical Oncology, Pathology, and Radiation Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Bryan Hennessy, MD, Dept of Medical Oncology, Box 10, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: bhennessy{at}mdanderson.org

PURPOSE: Squamous cell carcinoma (SCC) of the breast is rare and generally aggressive. In this study, we analyzed 33 patients treated at The University of Texas M.D. Anderson Cancer Center (Houston, TX) and a series of 137 patients identified through the Surveillance, Epidemiology, and End Results (SEER) database to make therapy recommendations.

METHODS: Records of The University of Texas M.D. Anderson Cancer Center were searched for patients diagnosed with breast SCC from 1985 to 2001. All biopsy material was reviewed by a dedicated breast pathologist who performed immunohistochemistry for hormone receptors and the epidermal growth factor receptor (EGFR). We searched the SEER database for patients with breast SCC diagnosed between 1988 and 2001.

RESULTS: We identified 33 patients with breast SCC, of whom two patients had metastatic disease at diagnosis. The median relapse-free survival (RFS) of 31 patients with localized disease was 20 months (range, 1 to 108 months), with a 26% RFS rate at 5 years. The median overall survival in these patients was 37 months (range, 12 to 108 months), with 40% surviving at 5 years. Median survival from the time recurrent disease was recognized was 14 months (range, 2 to 86 months). Tumors were usually hormone receptor–and HER2/neu-negative, though EGFR was frequently overexpressed. Information from the SEER database was consistent with most of our findings.

CONCLUSION: SCC of the breast is aggressive and often treatment-refractory. The role of platinum salts, EGFR inhibitors, and other novel agents needs to be explored.

Supported by the Nellie B. Connally Breast Cancer Research Fund and Cancer Center Support Grant No. P30 CA016672 29 from the National Cancer Institute.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				A. Rizki, V. M. Weaver, S.-Y. Lee, G. I. Rozenberg, K. Chin, C. A. Myers, J. L. Bascom, J. D. Mott, J. R. Semeiks, L. R. Grate, et al. A Human Breast Cell Model of Preinvasive to Invasive Transition Cancer Res., March 1, 2008; 68(5): 1378 - 1387. [Abstract] [Full Text] [PDF]